비소세포 폐암(NSCLC) 치료제 시장 규모, 점유율 및 성장 분석 : 치료법별, 암 유형별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Non-Small Cell Lung Cancer Therapeutics Market size was valued at USD 39.8 Billion in 2024 and is poised to grow from USD 42.1 Billion in 2025 to USD 66.05 Billion by 2033, growing at a CAGR of 5.79% during the forecast period (2026-2033).

The global Non-Small Cell Lung Cancer (NSCLC) therapeutics market encompasses a variety of treatment options, including targeted therapies, immunotherapies, and chemotherapy, aimed at improving patient outcomes and extending survival. The market's growth is driven by the high prevalence of NSCLC, significant healthcare costs associated with the disease, and ongoing funding for research from both public and private sectors. Advances in personalized therapy using biomarkers for mutation identification have revolutionized treatment approaches, enabling more effective drug targeting and enhancing adoption rates for medications like osimertinib and alectinib. Additionally, the integration of AI technologies in drug discovery is streamlining processes such as target identification and molecule creation, further propelling innovation in the NSCLC pharmaceutical landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Small Cell Lung Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Small Cell Lung Cancer Therapeutics Market Segments Analysis

Global non-small cell lung cancer therapeutics market is segmented by therapy type, cancer type, route of administration, distribution channel, end user and region. Based on therapy type, the market is segmented into Targeted Therapy, Immunotherapy, Chemotherapy, Anti-Angiogenic Therapy and Combination Therapy. Based on cancer type, the market is segmented into Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma. Based on route of administration, the market is segmented into Oral and Injectable/Intravenous. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Cancer Treatment Centers, Ambulatory Surgical Centers and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Small Cell Lung Cancer Therapeutics Market

One of the key market drivers for the global non-small cell lung cancer (NSCLC) therapeutics market is the rising prevalence of lung cancer globally, largely due to factors such as smoking, environmental pollutants, and genetic predispositions. This increasing incidence heightens the demand for effective treatment options, spurring research and development in targeted therapies and immunotherapies. Moreover, advancements in precision medicine and the emergence of novel biomarkers enable more personalized treatment approaches, resulting in improved patient outcomes. The growing awareness of lung cancer and ongoing investment in healthcare infrastructure further facilitate access to innovative therapies, fueling market growth.

Restraints in the Global Non-Small Cell Lung Cancer Therapeutics Market

One significant market restraint for the Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market is the high cost associated with innovative treatments and therapies. The financial burden of advanced targeted therapies and immunotherapies can be prohibitive for patients and healthcare systems, leading to limited access for a substantial segment of the population. Additionally, reimbursement challenges and varying levels of insurance coverage create disparities in treatment accessibility. The complexity of treatment regimens and the necessity for personalized medicine further complicate patient management, potentially resulting in delays or avoidance of necessary therapy, ultimately hindering overall market growth and patient outcomes.

Market Trends of the Global Non-Small Cell Lung Cancer Therapeutics Market

The Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics market is witnessing a significant trend towards the expansion of combination therapies, particularly utilizing immunotherapy drugs alongside other treatment modalities. Biopharma companies are increasingly exploring the synergetic potential of combining immunotherapies with angiogenesis inhibitors and other agents to tackle the complexities of cancer resistance and heterogeneity. This trend emphasizes the importance of biomarker subgroup selection, adaptive trial designs, and effective lifecycle management strategies to differentiate products in a competitive landscape. However, stakeholders, including payers and providers, are insisting on robust evidence highlighting sustained benefits and safety profiles, ensuring the viability of these innovative therapies.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Non-small Cell Lung Cancer Therapeutics Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Targeted Therapy
  • EGFR Inhibitors
  • ALK Inhibitors
  • ROS1 Inhibitors
  • KRAS Inhibitors
  • BRAF Inhibitors
  • MET Inhibitors
  • RET Inhibitors
  • HER2 Inhibitors
• Immunotherapy
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
  • CTLA-4 Inhibitors
• Chemotherapy
  • Platinum-Based Chemotherapy
  • Antimetabolites
  • Microtubule Inhibitors
• Anti-Angiogenic Therapy
• Combination Therapy

Global Non-small Cell Lung Cancer Therapeutics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Adenocarcinoma
• Squamous Cell Carcinoma
• Large Cell Carcinoma

Global Non-small Cell Lung Cancer Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable/Intravenous

Global Non-small Cell Lung Cancer Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

Global Non-small Cell Lung Cancer Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cancer Treatment Centers
• Ambulatory Surgical Centers
• Specialty Clinics

Global Non-small Cell Lung Cancer Therapeutics Market Size & CAGR (2026-2033)

• North America (Therapy Type, Cancer Type, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Therapy Type, Cancer Type, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Cancer Type, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Cancer Type, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Cancer Type, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Innovative Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Blueprint Medicines Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations